Long-term risk of adverse outcomes according to atrial fibrillation type

F. Eberli | D. Conen | K. Lovblad | A. Monsch | F. Lazeyras | S. Aeschbacher | N. Rodondi | D. Shah | A. Loewe | G. Ehret | D. Aujesky | D. Hayoz | A. Gallino | R. Kobza | P. Erne | D. Weishaupt | G. Dutilh | A. Auricchio | M. Amann | J. Schläpfer | P. Benkert | Simon Jung | S. Blum | P. Meyre | P. Krisai | C. Cereda | H. Mattle | M. Düring | J. Fuhrer | Milica Marković | M. Schwenkglenks | Ramun Schmid | T. Moccetti | U. Fischer | F. Regoli | B. Mehmann | L. Bonati | B. Berte | M. Caputo | G. Conte | L. Roten | T. Szucs | G. Montrasio | T. Sinnecker | F. Kellner-Weldon | É. Guillermet | A. Altermatt | C. Sticherling | J. Beer | A. Cianfoni | R. Paladini | M. Firmann | M. Di Valentino | N. Lauriers | J. Würfel | G. Moschovitis | R. Brenner | P. Ammann | C. Meyer-Zürn | M. Kühne | N. Bonetti | T. Reichlin | S. Osswald | C. Müller | M. Coslovsky | M. Méan | L. Vicari | C. Aubert | C. Terés | J. Novak | D. Altmann | Mirko Lischer | P. Baumgartner | R. Dillier | A. Porretta | Eva S. Laube | Patrizia Melchiorre | Damiana Rakovic | M. Feller | E. Moutzouri | L. Adam | N. Schwab | C. Schneider | F. Stephan | K. Schmidt | C. Eken | Pia Neuschwander | E. Rigamonti | P. Reddiess | Rahel Müller | Stefanie Chloé Steffen Leo Selinda David Simone Ceylan Marc Aeschbacher Auberson Blum Bonati Ceylan | C. Auberson | S. Ceylan | Simone Evers-Doerpfeld | Marc Girod | E. Hennings | Elena Herber | Vasco Iten | Maurin Lampart | A. Springer | G. Völlmin | S. Netzer | Tanja Flückiger | C. Groen | Lukas Ehrsam | Sven Hellrigl | Alexandra Nuoffer | Rylana Wenger | Tu Hanh Zarrabi Saffari | Christopher Beynon | Michèle Deubelbeiss | C. Franzini | Isabelle Juchli | C. Liedtke | Samira Murugiah | Jacqueline Nadler | Thayze Obst | J. Roth | F. Schlomowitsch | Xiaoye Schneider | Katrin Studerus | N. Tynan | Andreas Müller | Simone Fontana | Corinne Friedli | S. Kuest | Karin Scheuch | Denise Hischier | Alexandra Grau | J. Villinger | Mark G Filipovic | M. Frick | S. Leuenberger | F. Rutz | A. Anesini | Cristina Camporini | M. Gemperle | S. Foucras | Martine Rime | Virgina Justi | Sonja Meier | Myriam Roth | Andrea Ruckli-Kaeppeli | Ian Russi | Mabelle Young | Melanie Zbinden | M. L. De Perna | Jane Frangi-Kultalahti | A. Pin | T. Terrot | Hervé Gallet | P. Perret | Philip Tavel | Sandrine Salzmann | Andrea Grêt | Sandra Vitelli | H. Aebersold | Fabienne Foster | Petra Huber | E. Ruberte | V. Zuber | P. Simon | M. Rime | Chloé Auberson | A. Grêt | J. Beer | M. di Valentino | Simone Evers‐Doerpfeld | P. Melchiorre | C. Teres | Claudio Schneider | Marcello di Valentino | Adriana Anesini | Mark G. Filipovic | M. Lampart | Gian Völlmin | N. Rodondi | L. Bonati | E. Ruberte | Luisa Vicari

[1]  G. Lip,et al.  Adherence to the ‘Atrial Fibrillation Better Care’ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes—A Systematic Review and Meta-Analysis of 285,000 Patients , 2021, Thrombosis and Haemostasis.

[2]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[3]  B. Joung,et al.  Application of the simple atrial fibrillation better care pathway for integrated care management in frail patients with atrial fibrillation: A nationwide cohort study , 2020, Journal of arrhythmia.

[4]  D. Conen,et al.  Incidence and predictors of atrial fibrillation progression: A systematic review and meta-analysis. , 2019, Heart rhythm.

[5]  D. Conen,et al.  Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. , 2019, Journal of the American College of Cardiology.

[6]  G. Lip,et al.  Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study , 2018, Thrombosis and Haemostasis.

[7]  Tzeng-Ji Chen,et al.  Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.

[8]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[9]  Josef Kautzner,et al.  Corrigendum to: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2018, European heart journal.

[10]  G. Lip.  The ABC pathway: an integrated approach to improve AF management , 2017, Nature Reviews Cardiology.

[11]  N. Cook,et al.  Modifiable Risk Factors for Incident Heart Failure in Atrial Fibrillation. , 2017, JACC. Heart failure.

[12]  D. Conen,et al.  Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. , 2017, Swiss medical weekly.

[13]  D. Conen,et al.  Prospective Assessment of Sex‐Related Differences in Symptom Status and Health Perception Among Patients With Atrial Fibrillation , 2017, Journal of the American Heart Association.

[14]  G. Lip,et al.  Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care , 2017, Journal of the American Heart Association.

[15]  D. Conen,et al.  Uptake of non-vitamin K antagonist oral anti coagulants in patients with atrial fibrillation - a prospective cohort study. , 2017, Swiss medical weekly.

[16]  D. Singer,et al.  Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation , 2017, Circulation.

[17]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[18]  Prashanthan Sanders,et al.  The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. , 2016, European heart journal.

[19]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[20]  Sudha Seshadri,et al.  50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study , 2015, The Lancet.

[21]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[22]  N. Tanahashi,et al.  Clinical outcomes of persistent and paroxysmal atrial fibrillation in patients with stroke. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[23]  Helmut Pürerfellner,et al.  Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with implantable devices. , 2014, Journal of the American College of Cardiology.

[24]  JulienSeitz,et al.  Letter by Seitz and Beurtheret Regarding Article, “Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study” , 2014 .

[25]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[26]  J. Le Heuzey,et al.  Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study , 2013, Circulation.

[27]  Habib Gamra,et al.  Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice: Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry , 2012, Circulation. Arrhythmia and electrophysiology.

[28]  Huai Sheng Chen,et al.  Catheter ablation for paroxysmal and persistent atrial fibrillation. , 2012, The Cochrane database of systematic reviews.

[29]  Maarten L. Simoons,et al.  The third universal definition of myocardial infarction , 2013 .

[30]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[31]  C. Albert,et al.  Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. , 2011, JAMA.

[32]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[33]  W. Brown.  Framingham Heart Study. , 2011, Journal of clinical lipidology.

[34]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[35]  A. Stępień,et al.  Strokes in paroxysmal atrial fibrillation have more favorable outcome than in permanent atrial fibrillation , 2009, Acta neurologica Scandinavica.

[36]  J. Seward,et al.  Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. , 2006, European heart journal.

[37]  Dietrich Andresen,et al.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.

[38]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[39]  J. Murabito,et al.  Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study , 2003, Circulation.

[40]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[41]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.